Johnson & Johnson Stock Price, News & Analysis

Johnson & Johnson (NYSE: JNJ) will present 11 abstracts at the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Jan 12–15, 2026, in Nassau, Bahamas. Presentations cover Phase 3 and preclinical neuropsychiatry research across major depressive disorder (MDD), treatment-resistant depression (TRD), schizophrenia, and discovery work.

Key items include Phase 3 analyses of lumateperone (CAPLYTA) for remission in adjunctive MDD, metabolic and tolerability data comparing adjunctive seltorexant vs quetiapine XR in MDD with insomnia, and post-hoc Phase 3 analyses of esketamine (SPRAVATO) on anhedonia in TRD, plus AI and biomarker discovery posters.

Johnson & Johnson (NYSE:JNJ) reported longer-term Phase 1b/2 OrigAMI-1 results for amivantamab (RYBREVANT) combined with FOLFOX or FOLFIRI in RAS/BRAF wild-type metastatic colorectal cancer at ASCO GI 2026. At a median 16-month follow-up, confirmed ORR was 51% overall and 73% in the first-line subgroup; median DOR was 9.3 months overall and not reached in first-line. Median PFS was 9.2 months overall and 11.3 months in patients with liver metastases. Safety was consistent with known profiles; 9% discontinued for treatment-related adverse events and neutropenia was the most common Grade ≥3 event.

Johnson & Johnson (NYSE: JNJ) announced a voluntary agreement with the U.S. government to improve access to medicines, including participation in TrumpRx.gov to offer discounted prices to millions of American patients and an exemption for JNJ pharmaceutical products from U.S. tariffs. The company reaffirmed its $55 billion U.S. investment commitment through early 2029 and announced two new U.S. manufacturing facilities: a next‑generation cell therapy site in Pennsylvania and a drug product facility in North Carolina. Construction continues on a $2 billion biologics facility in Wilson, NC, expected to create ~5,000 skilled jobs; JNJ also secured a 160,000+ sq ft site in Holly Springs, NC.

Johnson & Johnson (NYSE: JNJ) submitted the OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration on January 7, 2026, requesting De Novo classification for multiple general surgery procedures in the upper abdomen.

The submission uses data from a completed Investigational Device Exemption (IDE) clinical study (first cases completed in early 2025) and targets procedures such as gastric bypass, gastric sleeve, small bowel resection and hiatal hernia repair. A second IDE was approved in late 2025 to begin a U.S. trial in inguinal hernia repair. The OTTAVA system remains under development and is not authorized for marketing or sale.

Johnson & Johnson (NYSE: JNJ) announced positive topline Phase 2b JASMINE results for nipocalimab in systemic lupus erythematosus (SLE) on January 6, 2026. The study met its primary endpoint (percentage achieving SRI-4 at Week 24 versus placebo) and key secondary/exploratory endpoints, including signals for steroid sparing. JASMINE enrolled 228 adults in a 52-week, randomized, double-blind, placebo-controlled, dose-ranging trial. Nipocalimab's safety and tolerability were consistent with prior Phase 2 studies with no new safety signals identified. Based on these topline results, the company plans to initiate a Phase 3 program for SLE; full study data will be presented at a future medical congress.

Johnson & Johnson (NYSE: JNJ) announced a quarterly cash dividend of $1.30 per share for Q1 2026. The dividend is payable on March 10, 2026 to shareholders of record at the close of business on February 24, 2026. The ex-dividend date is February 24, 2026.

Johnson & Johnson (NYSE: JNJ) completed the acquisition of Halda Therapeutics OpCo for $3.05 billion in cash on December 29, 2025. The deal brings a clinical-stage oral prostate cancer therapy, HLD-0915, plus earlier RIPTAC™ platform candidates for breast, lung and other solid tumors.

J&J said the acquisition will be treated as a business combination and expects a total Adjusted EPS dilution of ~$0.20, split equally between Q4 2025 and 2026 due to non-recurring equity, financing and integration charges. Full-year 2026 guidance commentary is scheduled for the January 21, 2026 earnings call.

Johnson & Johnson (NYSE: JNJ) announced on December 18, 2025 that the U.S. Food and Drug Administration approved an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for embolization of the middle meningeal artery (MMA) to treat symptomatic subacute and chronic subdural hematoma (cSDH) as an adjunct to surgery.

The approval is supported by the randomized MEMBRANE trial, which showed TRUFILL n‑BCA was superior in effectiveness to standard of care and was demonstrated to be safe for cSDH. TRUFILL n‑BCA has been used in neurovascular embolization for over 25 years, with original FDA approval in 2000.